Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery. There is particular interest in 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT)—a serotonergic psychedelic—as a novel, fast-acting therapeutic. Yet, few studies have directly...
MDMA therapy for PTSD. Those suffering from posttraumatic stress disorder (PTSD) may have a new treatment option—psychedelic therapy. In a confirmatory randomized controlled trial with 104 participants, researchers found that 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy reduced symptoms and functional impairment in people with moderate to severe PTSD. Their findings add to a...
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensive review of the current state of the field by applying a systematic search strategy for articles on the effectiveness and tolerability of four psychedelic-assisted therapies (psilocybin, lysergic acid diethylamide [LSD],...
Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved pharmacotherapy and psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we review clinical trials and research on...
Abstract: Rationale: A subanesthetic dose of ketamine, a non-competitive N-methyl-D-aspartate glutamate receptor (NMDAR) antagonist, elicits dissociation in individuals with posttraumatic stress disorder (PTSD), who also often suffer from chronic dissociative symptoms in daily life. These debilitating symptoms have not only been linked to worse PTSD trajectories, but also to increased...
Abstract Purpose This study tested whether stressful life events and stressful combat experiences are associated with post-traumatic stress symptomology (PTS-S), via facets of mindfulness, in UK military personnel.Methods A sample of 435 UK veterans were recruited to a cross-sectional, online study. Participants completed self-report measures of stressful life and combat experiences,...
The present study examined the associations between war-related exposure, nightmares, fear, insomnia, and PTSD symptoms among university students from Western Ukraine. An online cross-sectional study was performed among 1,072 university students (80% of whom were women) during the war. Eight questions were developed to assess exposure to war, and seven items were designed regarding nightmares...
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD). Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and...
The third part of a new study assessing MDMA‐assisted therapy, a psychedelic drug also known as Ecstasy, has revealed improvement in diverse individuals suffering with severe post‐traumatic stress disorder (PTSD). The study, “MDMA‐assisted therapy for moderate to severe PTSD: a randomized, placebo‐controlled phase 3 trial,” published Sept. 14 in Nature Medicine.